Insider Transactions in Q1 2025 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 20
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
899
-1.26%
|
$152,830
$170.99 P/Share
|
|
Feb 20
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
604
-1.49%
|
$102,680
$170.99 P/Share
|
|
Feb 19
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,031
-4.67%
|
$174,239
$169.71 P/Share
|
|
Feb 19
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
535
-0.74%
|
$90,415
$169.71 P/Share
|
|
Feb 19
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
287
-2.38%
|
$48,503
$169.71 P/Share
|
|
Feb 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
320
-1.74%
|
$54,080
$169.71 P/Share
|
|
Feb 19
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-0.92%
|
$63,206
$169.71 P/Share
|
|
Feb 19
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,936
-2.04%
|
$496,184
$169.71 P/Share
|
|
Feb 19
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-3.76%
|
$40,898
$169.71 P/Share
|
|
Feb 19
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.28%
|
$16,731
$169.71 P/Share
|
|
Feb 12
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,538
+17.05%
|
-
|
|
Feb 12
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
18,149
+11.18%
|
-
|
|
Feb 12
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.27%
|
-
|
|
Feb 12
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,815
+21.99%
|
-
|
|
Feb 12
2025
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,479
+4.62%
|
-
|
|
Feb 12
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,269
+15.83%
|
-
|
|
Feb 12
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,042
+9.99%
|
-
|
|
Feb 12
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,345
+5.43%
|
-
|
|
Feb 05
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
403
-8.02%
|
$66,092
$164.3 P/Share
|
|
Feb 05
2025
|
Vicky B Gregg Director |
SELL
Open market or private sale
|
Direct |
1,250
-6.9%
|
$205,000
$164.57 P/Share
|
|
Jan 29
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Small Acquisition
|
Direct |
57
+0.35%
|
$9,006
$158.04 P/Share
|
|
Jan 29
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Small Acquisition
|
Direct |
35
+0.2%
|
$5,530
$158.04 P/Share
|
|
Jan 29
2025
|
Vicky B Gregg Director |
BUY
Small Acquisition
|
Direct |
72
+0.4%
|
$11,376
$158.04 P/Share
|
|
Jan 29
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Small Acquisition
|
Direct |
4
+0.08%
|
$632
$158.03 P/Share
|
|
Jan 29
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Small Acquisition
|
Direct |
12
+0.12%
|
$1,896
$158.03 P/Share
|